Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1951 3
1952 2
1953 2
1955 1
1956 1
1957 2
1960 1
1962 1
1963 3
1964 3
1965 3
1966 4
1967 6
1968 3
1969 11
1970 7
1971 8
1972 14
1973 11
1974 17
1975 17
1976 12
1977 27
1978 10
1979 16
1980 25
1981 33
1982 34
1983 31
1984 38
1985 30
1986 31
1987 36
1988 40
1989 34
1990 33
1991 29
1992 31
1993 26
1994 24
1995 32
1996 28
1997 21
1998 25
1999 29
2000 21
2001 38
2002 36
2003 22
2004 30
2005 35
2006 38
2007 45
2008 54
2009 36
2010 45
2011 65
2012 53
2013 71
2014 83
2015 87
2016 79
2017 61
2018 60
2019 73
2020 70
2021 88
2022 61
Text availability
Article attribute
Article type
Publication date

Search Results

1,917 results
Results by year
Filters applied: . Clear all
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: gold r. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Oral Therapies for Multiple Sclerosis.
Faissner S, Gold R. Faissner S, et al. Among authors: gold r. Cold Spring Harb Perspect Med. 2019 Jan 2;9(1):a032011. doi: 10.1101/cshperspect.a032011. Cold Spring Harb Perspect Med. 2019. PMID: 29500302 Free PMC article. Review.
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Among authors: gold r. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. Montalban X, et al. Among authors: gold r. Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20. Mult Scler. 2018. PMID: 29353550
Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism.
Duscha A, Gisevius B, Hirschberg S, Yissachar N, Stangl GI, Eilers E, Bader V, Haase S, Kaisler J, David C, Schneider R, Troisi R, Zent D, Hegelmaier T, Dokalis N, Gerstein S, Del Mare-Roumani S, Amidror S, Staszewski O, Poschmann G, Stühler K, Hirche F, Balogh A, Kempa S, Träger P, Zaiss MM, Holm JB, Massa MG, Nielsen HB, Faissner A, Lukas C, Gatermann SG, Scholz M, Przuntek H, Prinz M, Forslund SK, Winklhofer KF, Müller DN, Linker RA, Gold R, Haghikia A. Duscha A, et al. Among authors: gold r. Cell. 2020 Mar 19;180(6):1067-1080.e16. doi: 10.1016/j.cell.2020.02.035. Epub 2020 Mar 10. Cell. 2020. PMID: 32160527 Free article.
Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution.
Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, Scheiwe C, Nessler S, Kunz P, van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, Gold R, Grün D, Priller J, Stadelmann C, Prinz M. Masuda T, et al. Among authors: gold r. Nature. 2019 Feb;566(7744):388-392. doi: 10.1038/s41586-019-0924-x. Epub 2019 Feb 13. Nature. 2019. PMID: 30760929
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism.
Haghikia A, Zimmermann F, Schumann P, Jasina A, Roessler J, Schmidt D, Heinze P, Kaisler J, Nageswaran V, Aigner A, Ceglarek U, Cineus R, Hegazy AN, van der Vorst EPC, Döring Y, Strauch CM, Nemet I, Tremaroli V, Dwibedi C, Kränkel N, Leistner DM, Heimesaat MM, Bereswill S, Rauch G, Seeland U, Soehnlein O, Müller DN, Gold R, Bäckhed F, Hazen SL, Haghikia A, Landmesser U. Haghikia A, et al. Among authors: gold r. Eur Heart J. 2022 Feb 10;43(6):518-533. doi: 10.1093/eurheartj/ehab644. Eur Heart J. 2022. PMID: 34597388 Free PMC article. Clinical Trial.
ROP Risk Management 2021.
Gold RS. Gold RS. Curr Opin Ophthalmol. 2021 Sep 1;32(5):494-497. doi: 10.1097/ICU.0000000000000790. Curr Opin Ophthalmol. 2021. PMID: 34397578 Review.
1,917 results